Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement
Argobio and GeneCode have announced their collaboration to develop small molecule Glial cell line - Derived Neurotrophic Factor (GDNF) mimetics for the treatment of Parkinson’s Disease and other indications.
In the venture studio model developed by Argobio, breakthrough technologies are embraced by a team of scientific experts with an entrepreneurial and industrial experience. Over the course of incubation, Argobio will fund the project development up to 3 ME and incorporate the start-up. After incubation, further venture funding will be provided by specialized VC investors.
“The launch of our first collaboration is a great achievement for Argobio. Argobio intends to incubate until series A at least five projects in the fields of rare diseases, neurosciences, and oncology over the next three years. With a committed capital of €50 million, and a team of pharma industry experts, Argobio expects to deliver strong projects, well-prepared for Series A funding,” Thierry Laugel Argobio Chairman said.
GeneCode, a discovery-stage biotech company developing small molecule GDNF mimetics, in collaboration with the laboratory of Mart Saarma, Professor and Research Director of the Institute of Biotechnology, HI-LIFE, University of Helsinki, Finland, has identified and patented a series of small molecules activating the GDNF signalling receptor RET tyrosine kinase. Professor Saarma´s team has discovered GDNF receptors, clarified the GDNF-receptor structure and investigated the therapeutic potential of GDNF family members.
Professor Mart Saarma commented, “Argobio’s investment and participation in the development of effective GDNF mimetics is extremely encouraging news. GDNF mimetics can overcome the limitations of the GDNF protein and can open up a completely new page in the treatment of Parkinson’s disease.”
GeneCode CEO Paavo Pilv added, “ Our combined expertise will catapult this technology beyond what we would have been able to achieve alone. Considering the pivotal role of GDNF family ligands and RET signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited only to Parkinson’s Disease but can be applied to treat other medical conditions.”
“We have ambitious goals for the next two years,” Argobio Entrepreneur in Residence Yves Ribeill, PhD said. “The whole is greater than the sum of the parts with the combined, diverse expertise of GeneCode, Argobio and Professor Saarma. I am confident that we will be able to demonstrate that the unique business model of funded partnerships initiated by Argobio in Europe will give new therapeutics a boost to succeed.”
About Argobio: www.argobiostudio.com
Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology, and immunology. Argobio selects and incubates these projects with the goal to create biotech companies and develop (or lead) them up to a significant Series A financing. Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio.
Follow us on LinkedIn.
About GeneCode: www.GeneCode.com
GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005337/en/
Contact information
NewCap – Media relations:
Nicolas Merigeau – nmerigeau@newcap.fr – +33 1 44 71 94 98
Arthur Rouillé – arouille@newcap.fr – +33 1 44 71 00 15
Argobio:
Yves Ribeill – yves.ribeill@argobiostudio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Telness Tech Appoints Octopus Group Chairman John Browett to Board of Directors30.7.2025 15:30:00 EEST | Press release
Telness Tech, the rapidly growing tech company reinventing telecom for modern mobile operators, today announced the appointment of John Browett to its Board of Directors. Browett brings decades of leadership and governance experience from some of the world’s most prominent companies, including Octopus Group, Apple, and Tesco. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730862294/en/ John Browett to join Telness Tech Board of Directors Browett currently serves as Chairman of Octopus Group, the company who founded Octopus Energy, whose Kraken Technologies platform has redefined how technology can transform traditional industries. He has also held executive leadership roles at Apple and Tesco, helping scale globally recognized businesses and pioneer large-scale e-commerce in one of Europe’s most competitive retail environments. “Telness Tech is doing to telecom what Kraken has done to the energy sector — rewriting the rul
Regula and Indicio Partner to Transform Identity Verification With Verifiable Credentials30.7.2025 15:30:00 EEST | Press release
Regula, a global developer of identity verification (IDV) solutions and forensic devices, enters a strategic technology partnership with Indicio, a market leader in Verifiable Credential technology and decentralized identity solutions. Together, the two companies will deliver a breakthrough in portable digital trust by issuing document and biometric identity verification solutions as tamper-proof Verifiable Credentials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730663365/en/ Regula x Indicio: Bridging the gap between physical IDs and tamper-proof digital credentials This collaboration between Regula and Indicio delivers a holistic infrastructure for creating, storing, and verifying digital identities, underpinned by the most robust verification technologies available today. After decades of forensic expertise and innovation in document and biometric verification technology, Regula has the most complete set of ID auth
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+30.7.2025 15:09:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and health advocate James Van Der Beek to increase awareness about colorectal cancer (CRC) screening and the Shield™ blood test. Approved by the U.S. Food and Drug Administration (FDA) last year, Shield offers a convenient and more pleasant new option for CRC screening for eligible individuals 45+. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250728751799/en/ Known for iconic roles in Varsity Blues, Rules of Attraction and Don’t Trust the B in Apartment 23, Van Der Beek has created many memorable characters in his 20+-year TV and film career, both on screen and as a producer, director and writer. Van Der Beek went public with his CRC diagnosis in November 2024 to encourage others to take control of their health. Today marks the first time he is speaking out about the critical importance of staying up to date
AI-Generated Code Poses Major Security Risks in Nearly Half of All Development Tasks, Veracode Research Reveals30.7.2025 14:50:00 EEST | Press release
Veracode, a global leader in application risk management, today unveiled its 2025 GenAI Code Security Report, revealing critical security flaws in AI-generated code. The study analyzed 80 curated coding tasks across more than 100 large language models (LLMs), revealing that while AI produces functional code, it introduces security vulnerabilities in 45 percent of cases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730694951/en/ Security and Syntax Pass Rates vs LLM Release from the Veracode 2025 GenAI Code Security Report The research demonstrates a troubling pattern: when given a choice between a secure and insecure method to write code, GenAI models chose the insecure option 45 percent of the time. Perhaps more concerning, Veracode's research also uncovered a critical trend: despite advances in LLMs’ ability to generate syntactically correct code, security performance has not kept up, remaining unchanged over time. “T
Promega Corporation Commits to Science Based Targets Initiative (SBTi) to Cut Greenhouse Gas Emissions30.7.2025 14:18:00 EEST | Press release
Promega Corporation, a global biotechnology manufacturer headquartered in Madison, Wisconsin, has committed to set near-term company-wide emission reductions with Science Based Targets initiative (SBTi). This begins a defined process to develop science-based targets for reducing greenhouse gas (GHG) emissions across the company’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250728306049/en/ Promega is committing to set company-wide greenhouse gas emission reductions with Science Based Targets initiative (SBTi). The move reflects the biotechnology manufacturer's focus on environmental stewardship shaped by scientific understanding. Kornberg Center, the company's research and development center in Madison, Wisconsin, was constructed to use 60% less energy than a comparable facility built to building codes. This action reflects Promega Corporation’s long-standing commitment to environmental stewardship, sha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom